|
Vaccine Detail
M-M-R II |
Vaccine Information |
- Vaccine Name: M-M-R II
- Target Pathogen: Rubella virus
- Target Disease: Rubella
- Product Name: Measles, Mumps, and Rubella Virus Vaccine, Live
- Tradename: M-M-R II
- Manufacturer: Merck & Co., Inc.
- Vaccine Ontology ID: VO_0000069
- CDC CVX code: 03
- Type: Live, attenuated vaccine
- Status: Licensed
- Location Licensed: USA(License #0002), Canada
- Host Species for Licensed Use: Human
- Allergen: Gelatin, Neomycin, Eggs
- Preparation: The growth medium for rubella is Minimum Essential Medium (MEM) [a buffered salt solution containing vitamins and amino acids and supplemented with fetal bovine serum] containing recombinant human albumin and neomycin. Sorbitol and hydrolyzed gelatin stabilizer are added to the individual virus harvests (FDA: MMR-II).
- Immunization Route: subcutaneous injection
- Storage: 2 to 8°C (36 to 46°F) or colder. Do not freeze.
- Approved Age for Licensed Use: 12 months or older
- Contraindication: Hypersensitivity to any component of the vaccine, a history of anaphylactic or anaphylactoid reactions to neomycin (FDA: MMR-II).
- Description: M-M-R II is a sterile lyophilized preparation of (1) ATTENUVAX* (Measles Virus Vaccine Live), a more attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture; (2) MUMPSVAX* (Mumps Virus Vaccine Live), the Jeryl Lynn** (B level) strain of mumps virus propagated in chick embryo cell culture; and (3) MERUVAX* II (Rubella Virus Vaccine Live), the Wistar RA 27/3 strain of live attenuated rubella virus propagated in WI-38 human diploid lung fibroblasts (FDA: MMR-II).
|
Host Response |
Human Response
- Immune Response: Neutralizing and ELISA antibodies to measles, mumps, and rubella viruses are still detectable in most individuals 11 to 13 years after primary vaccination (FDA: MMR-II).
- Side Effects: Side effects of vaccination are: fever, headache, dizziness, and irritability.
- Efficacy: Many clinical studies have shown the vaccine have a high rate of efficacy protection after vaccination with MMR-II (FDA: MMR-II).
|
References |
FDA: MMR-II: FDA: MMR-II Vaccine [http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094050.htm]
|
|